Search hospitals > Utah > Salt Lake City
Utah Cancer Specialists-Salt Lake City
Claim this profileSalt Lake City, Utah 84106
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Prostate Cancer
234 reported clinical trials
14 medical researchers
Summary
Utah Cancer Specialists-Salt Lake City is a medical facility located in Salt Lake City, Utah. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Utah Cancer Specialists-Salt Lake City is involved with conducting 234 clinical trials across 351 conditions. There are 14 research doctors associated with this hospital, such as Nicholas DiBella, Justin Call, Stephan Kendall, MD, and Ramya Thota.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Nicholas DiBellaRocky Mountain Cancer Centers-Boulder5 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
103 reported clinical trials
193 drugs studied
Justin CallSTART Mountain Region5 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Cancer
18 reported clinical trials
23 drugs studied
Stephan Kendall, MDUtah Cancer Specialists4 years of reported clinical research
Studies Prostate Cancer
Studies Follicular Lymphoma
8 reported clinical trials
21 drugs studied
Ramya ThotaIntermountain Medical Center7 years of reported clinical research
Studies Colorectal Cancer
Studies Adenocarcinoma
4 reported clinical trials
24 drugs studied
Clinical Trials running at Utah Cancer Specialists-Salt Lake City
Non-Small Cell Lung Cancer
Prostate Cancer
Lung Cancer
Bladder Cancer
Cancer
Breast Cancer
Multiple Myeloma
Squamous Cell Carcinoma
Colorectal Cancer
Plasma Cell Neoplasms
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Dato-DXd + Pembrolizumab
for Advanced Lung Cancer
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Recruiting2 awards Phase 313 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Utah Cancer Specialists-Salt Lake City?
Utah Cancer Specialists-Salt Lake City is a medical facility located in Salt Lake City, Utah. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Utah Cancer Specialists-Salt Lake City is involved with conducting 234 clinical trials across 351 conditions. There are 14 research doctors associated with this hospital, such as Nicholas DiBella, Justin Call, Stephan Kendall, MD, and Ramya Thota.